Search Within

Department of Medicine

Formats
  1. Journal Article (19620)
  2. Meeting Abstract (16084)
  3. Review (1158)
  4. Book Section (934)
  5. Editorial (611)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (237)
  10. Miscellaneous (91)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22367)
  2. Hematologic Malignancies, Division of (13308)
  3. Center for Hematologic Malignancies (11082)
  4. GSK Faculty (10658)
  5. Survivorship Research (9352)
  6. Division of Subspecialty Medicine (7560)

More Groups

People
  1. Robert Motzer (1251)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1158)
  2. 2024 (2293)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1411)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (904)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2898)
  5. Oxford University Press (2304)
  6. Nature Publishing Group (2122)

More Publishers

Results (39711)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Appearance-related psychosocial distress after facial non-melanoma skin cancer surgery: A 1-year prospective study
    Journal Article

    D'Hondt, V.; Veldhuizen, I. J.; Theelen, F.; Herlaar, S.; Lee, E. H.; Houterman, S.; Brinkhuizen, T.; Hoogbergen, M. M.
    Psycho-Oncology (2023)

    Fulltext@MSK | Save
  • Atezolizumab plus PEGPH20 versus chemotherapy in advanced pancreatic ductal adenocarcinoma and gastric cancer: MORPHEUS phase Ib/II umbrella randomized study platform
    Journal Article

    Ko, A. H.; Kim, K. P.; Siveke, J. T.; Lopez, C. D.; Lacy, J.; O'Reilly, E. M.; Macarulla, T.; Manji, G. A.; Lee, J.; Ajani, J.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Exploring influencing factors of anxiety improvement following mindfulness-based music therapy in young adults with cancer
    Journal Article

    Knoerl, R.; Mazzola, E.; Woods, H.; Buchbinder, E.; Frazier, L.; LaCasce, A.; Luskin, M. R.; Phillips, C. S.; Thornton, K.; Berry, D. L.; more...
    Journal of Music Therapy (2023)

    Fulltext@MSK | Save
  • TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (LISO‐CEL) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
    Meeting Abstract

    Morschhauser, F.; Dahiya, S.; Palomba, M. L.; Garcia‐Sancho, A. M.; Reguera Ortega, J. L.; Kuruvilla, J.; Jager, U.; Cartron, G.; Izutsu, K.; Dreyling, M.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 3 trial of subcutaneous epcoritamab + R‐CHOP versus R‐CHOP in patients (pts) with newly diagnosed diffuse large B‐cell lymphoma (DLBCL): EPCORE DLBCL‐2
    Meeting Abstract

    Sehn, L. H.; Chamuleau, M.; Lenz, G.; Clausen, M. R.; Haioun, C.; Izutsu, K.; Davies, A.; Zhu, J.; Oki, T.; Szafer‐Glusman, E.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (LISO‐CEL) in R/R MCL: Primary analysis results from the MCL cohort of the single-arm, multicenter, seamless design transcend NHL 001 study
    Meeting Abstract

    Wang, M.; Siddiqi, T.; Gordon, L. I.; Kamdar, M.; Lunning, M.; Hirayama, A. V.; Abramson, J. S.; Arnason, J.; Ghosh, N.; Mehta, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Daratumumab and EPOCH for HIV+/‐ plasmablastic lymphoma: A feasibility study of the AIDS Malignancy Consortium (AMC 105)
    Meeting Abstract

    Noy, A.; Barta, S. K.; Tan, C. R.; Kwon, D.; Baiocchi, R.; Rubinstein, P.; Ambinder, R.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • A phase I study of split‐course bringing radiotherapy (SC‐BRT) prior to commercial CD19 CAR T‐cell therapies for patients with relapsed or refractory B‐cell lymphomas
    Meeting Abstract

    Imber, B. S.; Yahalom, J.; Palomba, M. L.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • ZUMA‐24: A phase 2, open-label study of axicabtagene ciloleucel in patients with relapsed/refractory large B‐cell lymphoma given outpatient with corticosteroids
    Meeting Abstract

    Leslie, L.; Tees, M.; Flinn, I. W.; Rodriguez, T. E.; Baird, J. H.; Deol, A.; Mead, M.; Bachier, C.; Rapoport, A. P.; McClune, B.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 study of PRT1419 (MCL1 inhibitor) as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory myeloid or B‐cell malignancies
    Meeting Abstract

    Zuniga, R. R.; Nair, S.; Keiffer, G.; Ravandi‐Kashani, F.; Goldberg, A. D.; Traer, E.; Frenzel, L. P.; Röllig, C.; Savickas, G.; Sun, W.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save